Literature DB >> 29117354

Editorial: Challenges in Quantifying Overdiagnosis.

Stuart G Baker1, Philip C Prorok1, Barnett S Kramer1.   

Abstract

Mesh：

Year:  2017        PMID： 29117354      PMCID： PMC6279281          DOI： 10.1093/jnci/djx064

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  12 in total

1.  A reality check for overdiagnosis estimates associated with breast cancer screening.

Authors:  Ruth Etzioni; Jing Xia; Rebecca Hubbard; Noel S Weiss; Roman Gulati
Journal:  J Natl Cancer Inst       Date:  2014-10-31       Impact factor: 13.506

Review 2.  Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening.

Authors:  Ruth Etzioni; Roman Gulati; Leslie Mallinger; Jeanne Mandelblatt
Journal:  Ann Intern Med       Date:  2013-06-04       Impact factor: 25.391

3.  Lead time and overdiagnosis.

Authors:  Stuart G Baker; Philip C Prorok; Barnett S Kramer
Journal:  J Natl Cancer Inst       Date:  2014-10-31       Impact factor: 13.506

4.  Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.

Authors:  H Gilbert Welch; Philip C Prorok; A James O'Malley; Barnett S Kramer
Journal:  N Engl J Med       Date:  2016-10-13       Impact factor: 91.245

5.  Overdiagnosis in cancer screening: the need for a standardized denominator.

Authors:  Theodora M Ripping; André Lm Verbeek; Mireille Jm Broeders
Journal:  J Med Screen       Date:  2015-10-13       Impact factor: 2.136

6.  Latent class instrumental variables: a clinical and biostatistical perspective.

Authors:  Stuart G Baker; Barnett S Kramer; Karen S Lindeman
Journal:  Stat Med       Date:  2015-08-04       Impact factor: 2.373

Review 7.  Lead-time models should not be used to estimate overdiagnosis in cancer screening.

Authors:  Per-Henrik Zahl; Karsten Juhl Jørgensen; Peter C Gøtzsche
Journal:  J Gen Intern Med       Date:  2014-03-04       Impact factor: 5.128

Review 8.  The benefits and harms of breast cancer screening: an independent review.

Authors: 
Journal:  Lancet       Date:  2012-10-30       Impact factor: 79.321

9.  Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis.

Authors:  P-H Zahl; K J Jørgensen; P C Gøtzsche
Journal:  Br J Cancer       Date:  2013-08-20       Impact factor: 7.640

10.  Meta-analysis of breast cancer mortality benefit and overdiagnosis adjusted for adherence: improving information on the effects of attending screening mammography.

Authors:  Gemma Jacklyn; Paul Glasziou; Petra Macaskill; Alexandra Barratt
Journal:  Br J Cancer       Date:  2016-04-28       Impact factor: 7.640
View more
  2 in total

1.  Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials.

Authors:  Marc D Ryser; Roman Gulati; Marisa C Eisenberg; Yu Shen; E Shelley Hwang; Ruth B Etzioni
Journal:  Am J Epidemiol       Date:  2019-01-01       Impact factor: 4.897

2.  Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach.

Authors:  Thanya Pathirana; Andrew Hayen; Jenny Doust; Paul Glasziou; Katy Bell
Journal:  BMJ Open       Date:  2019-03-10       Impact factor: 2.692
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.